丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board of directors (the "**Board**") of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that, following review and approval by the nomination committee of the Board, the Board has resolved to nominate Ms. Zhu Linlin (朱琳琳女士) ("**Ms. Zhu**") as a candidate for non-executive director of the twelfth session of the Board, for a term commencing from the date on which her appointment is approved at the extraordinary general meeting of the Company (the "**EGM**") and ending upon the expiry of the term of the twelfth session of the Board. The proposed appointment of Ms. Zhu as a non-executive director of the Company is subject to consideration and approval by way of an ordinary resolution at the EGM.

Upon Ms. Zhu's appointment being approved and taking effect at the EGM, the Company will enter into a director's service agreement with Ms. Zhu. Ms. Zhu will be entitled to an annual director's fee of RMB96,000 (before tax) during her term of office as a non-executive director of the Company. Ms. Zhu's director's fee and remuneration will be determined by the Board with reference to her duties and responsibilities within the Company, the Company's remuneration policy and the market salary range for such position.

The biography of Ms. Zhu is set out below:

Ms. Zhu Linlin, aged 31, holds a master's degree in Applied Economics from Johns Hopkins University. Ms. Zhu has extensive experience in marketing, business development and corporate management in the pharmaceutical and healthcare industry.

From April 2022 to March 2023, Ms. Zhu worked at Joincare Pharmaceutical Group Industry Co., Ltd.* (a company listed on the Shanghai Stock Exchange, stock code: 600380, "**Joincare**") as the deputy marketing director of the Health Products Business Division. Ms. Zhu was responsible for brand building, product management and sales. During her tenure, she promoted the sales, marketing and distribution channel expansion of key brands. Joincare is one of the most comprehensive healthcare companies with the broadest business footprint in China, with its business covering five major segments, namely chemical preparations, active pharmaceutical ingredients, traditional Chinese medicine preparations, diagnostic reagents and healthcare products.

From April 2023 to February 2026, Ms. Zhu served as the general manager and vice chairwoman of Fluffy Buddy Animal Healthcare (Guangdong) Co., Ltd. ("**Fluffy Buddy Animal Healthcare**"). Since March 2026, she has served as the chairwoman of Fluffy Buddy Animal Healthcare. During such period, Ms. Zhu was fully responsible for the strategic planning, operation and management, research and development direction and business development of Fluffy Buddy Animal Healthcare. Under her leadership, Fluffy Buddy Animal Healthcare has achieved a number of business breakthroughs since its establishment and rapidly developed into an emerging domestic enterprise in the field of pet pharmaceutical products with independent research and development capabilities, compliant production qualifications and an extensive product pipeline. In terms of production qualifications and capacity development, Fluffy Buddy Animal Healthcare officially obtained the Veterinary Drug GMP Certificate and the Veterinary Drug Manufacturing Licence in December 2024, enabling it to conduct large-scale production of pet pharmaceutical products in multiple dosage forms, including tablets, drops, solutions and pastes. In terms of product development and approvals, Fluffy Buddy® Gabapentin Tablets, China's first prescription anti-stress drug for cats, were approved in 2025, filling the gap in the domestic market for compliant prescription anti-stress drugs for cats. Since 2026, Fluffy Buddy® Doxycycline Oral Paste, a Class II new veterinary drug independently developed by Fluffy Buddy Animal Healthcare, has been officially approved for marketing. The product is China's first broad-spectrum antibiotic in paste dosage form and is indicated for the treatment of infectious diseases in dogs and cats caused by bacteria susceptible to doxycycline. During the same period, Fluralaner Chewable Tablets and Fluralaner and Moxidectin Spot-on Solution also successively obtained registration approvals as Class II new veterinary drugs, further enriching the company's product portfolio. During her tenure at Fluffy Buddy Animal Healthcare, Ms. Zhu participated in advancing the international expansion of Fluffy Buddy Animal Healthcare by drawing on technical expertise and international regulatory compliance experience accumulated in the field of human pharmaceuticals.

Ms. Zhu is the daughter of Mr. Zhu Baoguo (朱保國先生), the actual controller of the Company. Save for the aforesaid family relationship, as at the date of this announcement, Ms. Zhu does not have any relationship with any other directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company or any of its subsidiaries.

As at the date of this announcement, Ms. Zhu serves as a director of PT Livzon Pharma Indonesia, an overseas subsidiary of the Company. Save as disclosed above, she does not hold any other position with the Company or any member of the Group.

Save as disclosed above, as at the date of this announcement, Ms. Zhu (i) has not held any directorship in any other listed company during the past three years and does not have any other major appointments or professional qualifications; (ii) has not been subject to any public sanction by any statutory or regulatory authority; and (iii) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters in relation to the proposed appointment of Ms. Zhu as a non-executive director that need to be brought to the attention of the shareholders of the Company, and there is no other information required to be disclosed pursuant to any of the provisions under Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Liu Ning
Company Secretary

Zhuhai, China
18 September 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (Chairman and President) and Mr. Tang Yanggang (Vice Chairman); the non-executive directors of the Company are Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee representative director of the Company is Ms. Ran Yongmei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

* *For identification purpose only*